https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-18 16:16:032026-05-18 16:16:23Hansa Biopharma participating at LSX Nordic Congress
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-05-18 16:16:032026-05-18 16:16:23Hansa Biopharma participating at LSX Nordic Congress
Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
Lund, Sweden, 12 March, 2026. Hansa Biopharma AB, “Hansa”…

Poolbeg Pharma plc – POLB 001 poster to be presented at EHA 2026 Congress
13 May 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026
TX001 is an engineered Regenerative Macrophage Therapy for…

AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
Brings more than 20 years of neurology, clinical development,…

ViCentra Announces Commercial Launch of New Smartphone-Controlled Kaleido Automated Insulin Delivery Patch Pump System
New system combines Kaleido with Diabeloop’s DBLG2 algorithm…

Poolbeg Pharma plc – POLB 001 cancer immunotherapy-induced CRS patent granted in Canada
Further strengthening of Poolbeg's global intellectual property…

ViaNautis Bio to present its targeted polyNaut® nanovesicles (tPNVs) for the generation of in vivo CAR-T therapies at ASGCT Annual Meeting
Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’…

Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment
Secures long‑term ownership and protection of Link_TSG6,…

Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy
AT-108 induces powerful, personalized anti-cancer responses…

Poolbeg Pharma plc – Results for the year ended 31 December 2025
28 April 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Oncoinvent ASA: Annual Report for 2025
Oslo, Norway, 22 April 2026 - Oncoinvent ASA (ONCIN), a biotech…

New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources
The Novo Nordisk Foundation Challenge Programme supports development…

Hansa Biopharma Report First Quarter 2026 Financial Results
· PDUFA target date set for December 19 by the FDA
·…

Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
Data demonstrates strong and higher secondary patency compared…

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization
CE mark awarded for aXess™ at record speed, underpinned…

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent…

New Nordic white paper reveals systemic barriers preventing women from reaching leadership roles
Report outlines 17 targeted actions to address structural barriers…

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
FB301 was safe and well tolerated in healthy female subjects,…

STORM Therapeutics secures $56 Million Series C financing and doses first patient in Phase 2 sarcoma trial of STC‑15
The proceeds will support the advancement of STC-15 in a Phase…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York